Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 718Lung Neoplasms 310Small Cell Lung Carcinoma 111Neoplasms 42Adenocarcinoma of Lung 40Neoplasm Metastasis 35Parkinson Disease 4, Autosomal Dominant Lewy Body 22Brain Neoplasms 21Carcinoma 19Breast Neoplasms 18Lung Diseases 15NSCLC 14Mesothelioma, Malignant 14Thoracic Neoplasms 13Adenocarcinoma, Bronchiolo-Alveolar 13Prostatic Neoplasms 11Pleural Effusion, Malignant 10Non-Squamous Non-Small Cell Lung Cancer 10Mesothelioma 10Cachexia 10Respiratory Tract Neoplasms 9Pain 9Bronchial Neoplasms 9Respiratory Tract Diseases 8Carcinoma, Squamous Cell 8Carcinoma, Bronchogenic 8Adenocarcinoma 8Pancreatic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7

Interventions

patritumab deruxtecan 1Platinum Compounds 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Nonsquamous Non-small Cell Lung Cancer × Thoracic × Clear all
NCT05338970 2025-01-31

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Daiichi Sankyo

Phase 3 Active not recruiting
586 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡